Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

venetoclax MeSH Supplementary Concept Data 2026


MeSH Supplementary
venetoclax
Unique ID
C579720
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C579720
Entry Term(s)
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
ABT-199
GDC-0199
RG-7601
RG7601
Venclexta
benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-
Pharm Action
Antineoplastic Agents
Registry Numbers
N54AIC43PW
Heading Mapped to
*Sulfonamides
*Bridged Bicyclo Compounds, Heterocyclic
Frequency
1222
Note
A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.
Source
Nat Med. 2013 Feb;19(2):202-8.
Date Introduced
2013/04/14
Last Updated
2016/10/06
venetoclax Preferred
ABT-199 Narrower
Venclexta Narrower
RG-7601 Narrower
GDC-0199 Narrower
page delivered in 0.007s